Study on the effectiveness of a nifedipine gel for treatment of Raynaud's phenomenon

Journal of Biological Regulators and Homeostatic Agents

Volumn 20, Issue 3-4, 2006, Pages 59-65

  Foti, C ^a   Quaranta, D ^a   Pepe, M L ^a   Morea, G ^b   Mastropasqua, D ^a   D'Amore, M ^a   Mastrangelo, F ^c   Tete S ^c   Grassi, F R ^a   Ballini, A ^a   Salini, V ^c   de Amicis, D ^c   Scagliusi, P ^a   de Lutiis, M A ^c   Caraffa, A ^d   Cerulli, G ^d  

^a UNIVERSITY OF BARI   (Italy)

^b Morea Pharmacy Bari   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Gel; Nifedipine; Raynaud's phenomenon; Therapy

Indexed keywords

NIFEDIPINE;

ADOLESCENT; ADULT; ARTICLE; CAPILLAROSCOPY; CAPILLARY FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GEL; HAND PARESTHESIA; HUMAN; MALE; RAYNAUD PHENOMENON; FINGER; PAIN;

FINGERS; HUMANS; NIFEDIPINE; PAIN; RAYNAUD DISEASE;

EID: 41949098509     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Sunderkotter C, Riemekasten G. Raynaud phenomenon in dermatology. Hautarzt 2006; 57 (9): 819-830.
2. Lazareth I. Management of Raynaud's phenomenon. Ann Dermatol Venereol 2001; 128: 553-556.
3. Castellani ML, Salini V, Frydas S, Donelan J, Madhappan B, Petrarca C, Vecchiet J, Falasca K, Neri G, Teté S. Interleukin-31: a new cytokine involved in inflammation of the skin. Int J Immunopathol Pharmacol 2006; 19:1-4.
4. Castellani ML, Salini V, Frydas S, Donelan J, Tagen M, Madhappan B, Petrarca C, Falasca K, Neri G, Tete' S, Vecchiet J. The proinflammatory interleukin-21 elicits anti-tumor response and mediates autoimmunity. Int J Immunopathol Pharmacol 2006; 19: 247-252.
5. Midulla F, Tromba V, Lo Russo L, Mileto F, Sabatino G, Sgarrella M, Panuska JR, Manganozzi L, Korn D, Moretti C. Cytokines in the nasal washes of children with respiratory syncytial virus bronchiolitis. Int J Immunopathol Pharmacol 2006; 19: 231-236.
6. Norman-Streiner. Biostatistica. Casa Editrice Ambrosiana 2004.
7. Freedman R, Ianni P, Lynn S. Treatment of Raynaud's phenomenon with biofeedback and cold desensitization. Psychophysiol 1970; 16: 182-195.
8. Freedman R, Ianni P, Wening P. Behavioral treatment of Raynaud's disease: Long term follow up. J Consult Clin Psychol 1985; 5: 136-148.
9. Inoue K, Takano H, Oda T, Yanagisawa R, Tamura H, Ohno N, Adachi Y, Ishibashi K, Yoshikawa T. Candida soluble cell wall β-D-glucan induces Lung inflammation in mice. Int J Immunopathol Pharmacol 2007; 20: 499-507
10. Greco C, D'Agnano I, Vitelli G, Vona R, Marino M, Mottolese M, et al. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol 2006; 19: 67-80.
11. Shim JY, Han Y, Ahn JY, Yun YS, Song JY. Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice. Int J Immunopathol Pharmacol 2007; 20: 487-498
12. Freedman R, Lynn S, Ianni P, Hale P. Biofeedback treatment of Raynaud's disease and phenomenon. Biofeedback and Self Regulation 1981; 6: 355-365.
13. Guglielmi RS, Roberts AH, Patterson R. Skin temperature biofeedback for Raynaud's disease: a double-blind study. Biofeedback and Self Regulation 1982; 7: 99-120.
14. 2in rat brain cultured astrocytes. Int J Immunopathol Pharmacol 2006; 19: 293-308.
15. Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E. Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 2007; 20: 435-446
16. Trubiani O, Orsini G, Caputi S, Piattelli A. Adult mesenchymal stem cells in dental research: a new approach for tissue engineering. Int J Immunopathol Pharmacol 2006; 19: 451-460.
17. Jobe JB, Sampson JB, Roberts DE, Kelly JA. Comparison of behavioural treatments for Raynaud's disease. Journal of Behavioral Medicine 1986; 9: 89-96.
18. Keefe FJ, Surwit RS, Pilon RN. Biofeedback, autogenic training, and progressive relaxion in the treatment of Raynaud's disease: A comparative study. Journal of Applied Behavior Analysis 1980; 13: 3-11.
19. Middaugh SJ, Haythornthwaite JA, Thompson B, Hill R, Brown KM, Freedman RR et al. The Raynaud's Treatment Study: Biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback 2001; 26: 251-278.
20. Peterson LL, Vorhies C. Raynaud's syndrome. Treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol 1983; 119: 396-399.
21. Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behaviour? Int J Immunopathol Pharmacol 2006; 19: 171-180.
22. Marino F, Guasti L, Cosentino M, De Piazza D, Simoni C, Bianchi V, et al. Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies. Int J Immunopathol Pharmacol 2006; 19: 149-160.
23. Marasini B, Belloli L, Massarotti M. Interstitial lung disease in systemic sclerosis. Int J Immunopathol Pharmacol 2007; 20: 223-228.
24. Raynaud's Treatment Study Investigators. Comparison of sustained release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1 year follow up. Arch Intern Med 2000; 160: 1101-1108.
25. Belch JJ, Steinberg M, Murphy E et al. Ann Rheum Dis 1995; 3: 197-205.
26. Stassi G, Cascio A, Iaria C, Gazzara D, Costa GB, Iannello D, Arena A. Modulation of GRO-α and TNF-α production by peripheral blood mononuclear cells treated with killed helicobacter pylori. Eur J Inflamm 2007; 5: 83-88
27. Marino F, Guasti L, Cosentino M, De Piazza D, Simoni C, Bianchi V, et al. Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies. Int J Immunopathol Pharmacol 2006; 19: 149-160.
28. Lanzilli G, Falchetti R, Cottarelli A, Macchi A, Ungheri D, Fuggetta MP. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol 2006; 19: 551-560.
29. Belch JJ, Ho M. Drugs 1996; 52: 682-694.
30. Isemberg DA, Black C. ABC of Rheumatology: Raynaud's phenomenon, scleroderma, and overlap syndromes. BMJ 1995; 310: 795-798.
31. Thompson AE, Shea B et al.Calcium Channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2003; 48: 282-283.
32. Marcucci F, Sensi L, Di Cara G, Gidaro G, Incorvaia C, Frati F. Sublingual reactivity to rBET V1 and rPHL P1 in patients with oral allergy syndrome. Int J Immunopathol Pharmacol 2006;19: 141-148.
33. Ogilvie ALJ, Lüft M, Antoni C, Schuler G, Kalden JR, Lorenz H-M: Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R p60 in psoriatic ski is driven by TNF-a. Int J Immunopathol Pharmacol 2006; 19: 271-278.
34. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta analysis. Rheumatology (Oxford) 2005; 44: 145-150.
35. Wigley FM. Raynaud's phenomenon. N Engl J Med. 2002; 347: 1001-1008.
36. Sperandeo M, Varriale A, D'Amico G, Sperandeo G, Piattelli ML, De Cata A, Greco A, Prigigallo F, Annese MA, Cedrone L, Vendemiale G. Intrarenal resistive index in patients with type 2 diabetes mellitus with and without microalbuminuria. Eur J Inflamm 2007; 5: 103-110
37. Cantaluppi V, Deregibus MC, Biancone L, Deambrosis I, Bussolati B, Albini A, et al. The expression of CD154 by Kaposi's sarcoma cells mediates the anti-apoptotic and migratory effects of HIV-1-Tat protein. Int J Immunopathol Pharmacol 2006; 19: 81-96.
38. Ahangari G, Z Chavoshzadeh, Z Lari, A Ramyar, A Farhoudi. Novel mutation detection of an inflammatory molecule Elastase II gene encoding neutrophil Elastase in Kostmann syndrome. Eur. J. Inflamm 2007; 5: 65-71
39. Jiang F, Li WP, Kwiecien J, Turnbull J. A study of the purine derivative AIT-082 in G93A SOD1 transgenic mice. Int J Immunopathol Pharmacol 2006;19:489-498.
40. Zhu W, Mantione KJ, Kream RM, Cadet P, Stefano GB. Cholinergic regulation of morphine release from human white blood cells: evidence for a novel nicotinic receptor via pharmacological and microarray analysis. Int J Immunopathol Pharmacol 2007; 30: 229-238.
41. Herrick AL. Tratment of Raynaud's phenomenon: new insights and developments. Curr Rheumatol Rep 2003; 5: 168-174.
42. Torley HI, Madhock R, Capell HA et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991; 50: 800-804.
43. Lo Muzio L, Santarelli A, Emanuelli M, Pierella F, Sartini D, Staibano S, Rubini C, De Rosa G. Genetic analysis of oral squamous cell carcinoma by cDNA microarrays focused apoptotic pathway. Int J Immunopathol Pharmacol 2006; 19: 675-682.
44. Pugliese L, Bernardini I, Viola-Magni MP, Albi E. Low levels o serum cholesterol/phospholipids are associated with the antiphospholipid antibodies in monoclonal gammopathy. Int J Immunopathol Pharmacol 2006; 19: 331-338.
45. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia-new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006; 19: 5-10
46. Pope J, Fenlon D et al. Iloprost and Cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; 2: CD000953.
47. Katzung BG. Farmacologia generale e clinica. Piccin 2003.
48. Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behaviour? Int J Immunopathol Pharmacol 2006; 19: 171-180.
49. Marino F, Guasti L, Cosentino M, De Piazza D, Simoni C, Bianchi V, et al. Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies. Int J Immunopathol Pharmacol 2006; 19: 149-160.
50. Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC. Anti-chemokine therapy for inflammatory diseases. Int J Immunopathol Pharmacol 2007; 20: 447-454
51. Capoluongo E, Vento G, Ameglio F, Lulli P, Matassa PG, Carrozza C, et al. Increased levels of IGF-1 and Beta2-microglobulin in epithelial lining fluid of preterm newborns developing chronic lung disease. Effects of rhG-CSF. Int J Immunopathol Pharmacol 2006; 19: 57-66.
52. Goodman Gilman. Le basi farmacologiche della terapia. Zanichelli 1998.
53. Masotti A, Mangiola A, Sabatino G, Maira G, Denaro L, Conti F, et al. Intracerebral diffusionofparamagnetic cationic liposomes containing Gd(DTPA)2- followed byMRI spectroscopy: assessment of pattern diffusion and time steadiness of a non-viral vector model. Int J Immunopathol Pharmacol 2006; 19: 379-390.
54. Mayerhofer M, Aichberger KJ, Florian S, Valent P. Recognition-sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense. Int J Immunopathol Pharmacol 2007; 20: 421-434.
55. Choucair N, Laporte V, Levy R, Tranchant C, Gies J-P, Poindron P, et al. The role of calcium and magnesium ions in uptake of b-amyloid peptides by microglial cells. Int J Immunopathol Pharmacol 2006; 19: 683-696.
56. Passam FH, Alexandrakis MG, Moschandrea J, Sfiridaki A, Roussou PA, Siafakas NM. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol 2006; 19: 161-170.
57. Lakota K, Mrak-Poljšak K, Rozman B, Kveder T, Tomšič M, Sodin-Semrl S. Serum amyloid A activation of inflammatory and adhesion molecules in human coronary artery and umbilical vein endothelial cells. Eur J Inflam 2007; 5: 73-81.
58. 1 ethyl ester for the treatment of trophic acral skin lesions in a patient with systemic scleroderma. J Eur Acad Dermatol Venereol 2002; 16: 526-528.